Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,248 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional

Study in Patients With COPD

NCT00215423
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
5 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
7
States / cities
Phoenix, Arizona • Wheat Ridge, Colorado • Hines, Illinois + 4 more
Conditions
Infections, Heart Failure, COPD Exacerbation, Asthma, Gastrointestinal Diseases, Cardiac Event, Arrythmia, Renal Failure, Renal Disease, Rheumatic Diseases, Urologic Diseases, Neurologic Disorder, Hematologic Diseases, Oncology Problem, Shock, Critical Illness
Interventions
Health Information Exchange (HIE) platform
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
4
States / cities
San Antonio, Texas • Seattle, Washington
Conditions
Insomnia
Interventions
CBT-I
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Conditions
Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions
Care Coordination
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Not listed
Enrollment
18,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA, DISKUS
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Jasper, Alabama • Riverside, California • Clearwater, Florida + 14 more
Conditions
Emphysema or COPD
Interventions
Interlobar fissure completion and pleural adhesiolysis
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Astegolimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 29 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Loxahatchee Groves, Florida • Miami, Florida • Rock Hill, South Carolina + 1 more
Not yet recruiting Not applicable Interventional

MOBoxy: MoblO2 to Maintain Oxygenation

NCT07222592
Conditions
COPD, Interstitial Lung Disease
Interventions
MoblO2 control
Device
Lead sponsor
National Jewish Health
Other
Eligibility
25 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Conditions
COPD
Interventions
Transcutaneous Electrical Muscle Stimulation (TCEMS), Sham TCEMS
Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers

Short Chain Fatty Acid Metabolism in COPD

NCT03327181
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
short chain fatty acid tracers
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
College Station, Texas
Conditions
COPD
Interventions
Lifestyle physical activity - self-efficacy
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Conditions
COPD
Interventions
Active smoking of Tobacco Hookah for 2 hours, Exposure to tobacco hookah second hand smoke, Visit a win bar
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Aurora, Colorado • Decatur, Georgia • Boston, Massachusetts + 2 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more
Conditions
COPD Exacerbation
Interventions
Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Copd
Interventions
TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 12 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more
Terminated Not applicable Interventional Results available

Consequences of Nocturnal and Daytime Hypoxemia in COPD

NCT00547456
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Oxygen
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New Hyde Park, New York